Identifying biomarkers for cerebral amyloid angiopathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The SENECA project is an Italian multicenter cohort study focused on cerebral amyloid angiopathy (CAA), a significant cause of intracerebral hemorrhage and cognitive decline in the elderly. This observational study aims to define the natural history of CAA and identify clinical and neuroradiological markers that indicate disease progression. By integrating the expertise of neurologists, neuroradiologists, neuro-ophthalmologists, and biologists, the study will collect a comprehensive dataset and biorepository from well-characterized CAA patients. The findings are expected to enhance clinical management guidelines and inform future treatment development.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All consecutive patients ≥55 years (with the exception of genetic cases), referred to the participating centres, with a diagnosis of possible probable and definite symptomatic or asymptomatic CAA, defined according to the modified Boston neuroradiological criteria, who had undergone at least one brain MRI (mandatory requirement for inclusion of the patient in the study) will be recruited.

Exclusion Criteria:

* evidence of other causes of cerebral hemorrhage (brain tumors, arteriovenous malformations, aneurysms, cavernous angiomas), contraindications to brain MRI, pregnancy and breastfeeding

Where it's running

• UOC Neurologia 5
  Milan, Milano, Italy Recruiting

Study contacts

• Study coordinator: Anna Bersano, MD, Phd
• Email: anna.bersano@istituto-besta.it
• Phone: +39022394

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Jiedu Huayu oral medicine for brain hemorrhage due to cerebral amyloid angiopathy

  This trial tests a traditional Chinese medicine oral prescription against placebo to see if it can reduce recurrent vascular events in patients with cerebral amyloid angiopathy-related intracerebral hemorrhage.

  Recruiting Phase 3 Beijing Tiantan Hospital · Beijing · NCT07250035

• Colchicine to prevent repeat lobar brain bleeds from cerebral amyloid angiopathy

  This trial will test whether taking a daily low-dose colchicine pill for a year is safe and helps prevent repeat lobar intracerebral hemorrhage in people with cerebral amyloid angiopathy who are at high risk of another bleed.

  Recruiting Phase 2 Huashan Hospital · Beijing and 2 other locations · NCT07026994

• Impact of the Mediterranean Diet on patients with CADASIL and Cerebral Amyloid Angiopathy

  This study is testing whether following the Mediterranean Diet can help people with CADASIL and Cerebral Amyloid Angiopathy feel better and reduce their risk of strokes and cognitive decline.

  Recruiting Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Milan · NCT06933212

• Using a digital twin app to support people in secondary prevention after stroke, Moyamoya disease, or cerebral amyloid angiopathy

  This trial will try the STRATIF-AI app plus usual secondary prevention care to see if it improves daily self-care and the patient experience for adults after stroke, Moyamoya disease, or CAA.

  Recruiting Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Milan, Michigan · NCT06714097

• Understanding the prognosis of cerebral small vessel disease

  This study looks at how different types of cerebral small vessel disease affect the health and future outcomes of patients, including issues like bleeding in the brain and memory problems.

  Recruiting Insel Gruppe AG, University Hospital Bern · Bern · NCT05734378

• Evaluating AMDX-2011P for treating cerebral amyloid angiopathy

  This study is testing a new drug called AMDX-2011P to see if it is safe and effective for people with cerebral amyloid angiopathy.

  Recruiting Phase 2 Amydis Inc. · Phoenix, Arizona · NCT05709314

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.